Issue of warrants

Advanced Oncotherapy PLC

16 June 2023

 

16 June 2023

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Issue of Warrants

Further to the Company's announcement on 12 December 2022, Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that it has, on 14 June 2023, issued warrants to subscribe for 12,000,000 new Ordinary Shares. The warrants were issued per the terms of the £1,500,000 equity subscription announced on 12 December 2022.

The warrants have an exercise price of 25 pence per share and are exercisable until 15 December 2027.

The issue of warrants has been conducted under the Company's existing share authorities and, notwithstanding the announcement made by the Company on 12 December 2022, the Company can confirm that it does not require to convene a general meeting to put in place new share authorities for this warrant issue.

Following this issuance of warrants the Company has a total of 199,061,873 warrants in issue.

- ENDS -

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
WH Ireland Limited (Financial adviser)	Tel: [phone]
Antonio Bossi / James Bavister	[e-mail]
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales & Corporate Broking)	Tel: [phone]
SI Capital Ltd (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END